Acasă › Boala Crohn › Texas › Tyler
Studii clinice pentru Boala Crohn în Tyler, TX
16 studii pentru Boala Crohn caută participanți în și în jurul orașului Tyler (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
În curs de recrutareFaza 3
- Tyler Research Institute ( Site 0294), Tyler
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
În curs de recrutareFaza 3
- Tyler Research Institute ( Site 5001), Tyler
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
În curs de recrutareFaza 2
- Tyler Research Institute /ID# 265545, Tyler
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
În curs de recrutareFaza 3
- The University of Texas Health Science Center at Tyler, Tyler
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
În curs de recrutareFaza 2/3
- Tyler Research Institute, LLC, Tyler
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
În curs de recrutareFaza 2
- Tyler Research Institute, LLC, Tyler
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
În curs de recrutareFaza 3
- Tyler Research Institute, Tyler
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
În curs de recrutareFaza 3
- Tyler Research Institute, LLC-Site Number: 8400095, Tyler
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
În curs de recrutareFaza 3
- Tyler Research Institute LLC-Site Number: 8400095, Tyler
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
În curs de recrutareFaza 2
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
În curs de recrutareFaza 4
- Tyler Research Institute, LLC, Tyler
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
În curs de recrutareFaza 3
- Tyler Research Institute, LLC, Tyler
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
În curs de recrutareFaza 3
- Tyler Research Institute, LLC, Tyler
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
În curs de recrutareFaza 2
- Tyler Research Institute, LLC, Tyler
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
În curs de recrutareFaza 2
- Tyler Research Institute, LLC, Tyler
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
În curs de recrutareFaza 2
- Mirador Therapeutics Selected Site, Tyler
Studii pentru Boala Crohn în alte orașe
- New York City, NY35 studii
- Cleveland, OH19 studii
- St. Louis, MO19 studii
- Boston, MA19 studii
- Miami, FL19 studii
- Orlando, FL17 studii
- Houston, TX17 studii
- Atlanta, GA17 studii
- San Diego, CA15 studii
- San Antonio, TX15 studii
- Los Angeles, CA15 studii
- Philadelphia, PA13 studii
Alte studii în Tyler
- Cancer pulmonar cu celule non-pătrate20 studii
- Colită ulcerativă14 studii
- Cancer colorectal8 studii
- Insuficiență cardiacă8 studii
- Cancer (toate tipurile)7 studii
- Cancer ovarian7 studii
- Cancer endometrial6 studii
- Carcinom cu celule scuamoase de cap și gât6 studii
- Cancer de sân6 studii
- Cancer metastatic5 studii
- Boală inflamatorie intestinală5 studii
- Leucemie limfatică cronică5 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.